Moreover, metformin selectively improved the overall survival of HCC patients with low DOCK1 expression in our cohort (Figs. 5A–C and S5A), supporting our conclusion that DOCK1 determines the therapeutic outcome of metformin treatment, and highlighting the clinical significance of our findings. Here, DOCK1 is linked to hepatocellular carcinoma.